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Identifying Biomarkers in Pediatric Rare Lung Disease
chILD Grows Up
Children’s interstitial and diffuse lung disease (chILD) has been
recognized as distinct from adult interstitial lung diseases for nearly 2
decades after the first descriptions of disorders of surfactant metabolism
and neuroendocrine cell hyperplasia of infancy (NEHI) (1, 2). In that
interval, advances in clinical phenotyping, histopathology, genetic
testing, and imaging have improved diagnostic capabilities and led to
the discovery of novel chILD disorders (3). However, although blood-
or airway-derived biomarkers can be informative in adult ILD (4, 5),
similar biomarkers do not exist in chILD, and lung biopsy is often still
required to make a definitive diagnosis. In recognition of these
limitations, a recent National Heart, Lung, and Blood Institute
workshop to advance chILD identified a “lack of validated biomarkers
or outcome measures suitable for use in infants and young children” as
a key gap (6). In this issue of the Journal, Deterding and colleagues (pp.
1496–1504) help to address this gap through the use of aptamer-based
proteomics to identify proteins and related pathways in BAL fluid that
distinguish two of the most common chILD disorders (NEHI and
disorders of surfactant metabolism) from each other and from control
individuals without chILD (7). Although this was a single-center study
on a relatively small population, these findings represent a significant
step forward in the study of these rare lung diseases.
The identification of unique protein signatures for both NEHI and
surfactant protein deficiency could have substantial diagnostic value. Both
disorders typically present similarly, with tachypnea, crackles, and
hypoxemia starting before 1 year of age (8). Although findings on chest
computed tomography (CT) are often diagnostic, nearly a quarter of
patients with biopsy-proven NEHI have atypical findings on chest CT (9),
and there are reported cases of a NEHI pattern on chest CT that were
ultimately found to be caused by surfactant dysfunction (10). Genetic
testing can also be informative, although approximately 25% of patients
who have lung biopsy consistent with surfactant dysfunction have negative
genetic studies (8). Reliance on genetic studies can also delay diagnosis and
treatment, as current testing often requires up to 4 weeks for completion.
This delay has meaningful treatment implications, as surfactant
dysfunction is typically treated with multiple medications such as
hydroxychloroquine, azithromycin, and corticosteroids (1), whereas the
therapy for NEHI is supportive care. Thus, a validated BAL proteomic
signature could improve diagnostic accuracy, allow more rapid
intervention in critically ill children, and reduce the need for lung biopsy in
those patients in whom radiologic and genetic studies are indeterminate.
The protein signatures identified in this study also offer exciting
potential insights into disease mechanisms and possible new therapeutic
targets. This is particularly important for NEHI, which, although
relatively common (by chILD standards), is poorly understood from a
mechanistic standpoint. Lung biopsies performed on patients with
NEHI show increased pulmonary neuroendocrine cells, which function
as innervated sensory cells within the lungs (11). However, it is unclear
how abnormalities within this cell type lead to hypoxemia, as the lung
parenchyma in patients with NEHI is almost normal on biopsy (2).
The cell signaling and metabolic pathways identified in this study offer
new pathways to investigate and may provide mechanistic insight.
Interestingly, the proteomic signatures suggested two distinct endotypes
in NEHI. This may indicate that NEHI represents two separate
disorders, although both had similar clinical outcomes. In surfactant
protein deficiency, the identification of pathways involved in fibrosis
offers hope that work in adult inflammatory-fibrosis lung models may
be relevant to these rare disorders. This is particularly important, as
many patients with surfactant dysfunction, particularly those with
pathologic variants in ABCA3 (ATP-binding cassette subfamily A
member 3), have significant mortality (12), and therefore medications
that slow progression are needed. Also, most patients with surfactant
dysfunction that present in childhood have progressive disease, so
antifibrotic medications developed for adult ILD may be beneficial.
Although the findings of this study represent an exciting advance in
chILD, the conclusions must be viewed with some caution, as the study
was small (understandable, given the low prevalence of chILD) and
lacked an independent validation cohort. Although the authors used
appropriate statistical methods to minimize bias, the relationships
between the identified pathways and disease pathophysiologywill remain
uncertain until validated through independent study. Furthermore,many
of the markers elevated in the surfactant dysfunction group have also
been associated with neutrophilic airway inflammation in other diseases
(13), which was elevated in this cohort. Further investigation will be
needed to identify which are specific to surfactant dysfunction.
Overall, this study by Deterding and colleagues offers an
exciting first step toward developing biomarker-based evaluation of
chILD. Although bronchoscopy and BAL is not without risk, it offers
a significant benefit over lung biopsy, particularly in critically ill
children. With appropriate validation, this study could represent a
critical first step toward developing improved biomarker-based
diagnostic and treatment strategies for pediatric rare lung disease.n
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Nintedanib and Sildenafil in Patients with Idiopathic
Pulmonary Fibrosis
Echoes of the Past, Lessons for the Future
Pulmonary hypertension (PH) commonly complicates the course
of patients with idiopathic pulmonary fibrosis (IPF). It is associatedwith
impaired functional ability and worse survival (1). The prevalence of
PH has a variably reported range between 15% in those with mild to
moderate restriction and 84% in those with more advanced disease
(2, 3). The high end of this range underscores that most patients are
likely to develop PH as their disease progresses. The increasing
armamentarium of drugs to treat pulmonary arterial hypertension has
raised the notion of therapy for PH complicating IPF. It remains
uncertain whether the presence of PH is the driver of worse outcomes
or whether it is a surrogate for disease severity. If it is indeed an
adaptive phenomenon, then ameliorating this may not result in benefit
and, worse yet, might result in harm. In contrast, if PH in this setting is
a maladaptive response, then targeting it may result in beneficial
outcomes.
The INSTAGE (Efficacy and Safety ofNintedanibCo-administered
with Sildenafil in Idiopathic Pulmonary Fibrosis Patients with Advanced
Lung Function Impairment) study was a prospective, double-blind,
randomized clinical trial comparing the benefits of nintedanib
with those of nintedanib plus add-on sildenafil in patients with IPF with
single-breath DLCO ,35% predicted (4). This major inclusionary
criterion replicated that of the STEP-IPF (Sildenafil Trial of Exercise
Performance in Idiopathic Pulmonary Fibrosis) study, which examined
the effects of sildenafil versus placebo in patients with IPF (5). Among
patients with IPF with DLCO,35%, the prevalence of PH is about 50%,
and in this regard, this cutpoint represents an enrichment strategy for
underlying resting PH (6). The INSTAGE study failed to meet its primary
endpoint of a change in the St. George’s Respiratory Questionnaire at
12 weeks, but there was a favorable trend in a number of secondary
endpoints, including the University of California, San Diego, Shortness
of Breath questionnaire, as well as a salutary effect on FVC change.
Therefore, although it was a negative study based on the chosen
primary endpoint, the INSTAGE study was suggestive of a possible
benefit, perhaps best demonstrated in a further enriched population.
In this issue of the Journal, Behr and colleagues (pp. 1505–
1512) present a post hoc analysis of the INSTAGE cohort,
categorized by the presence or absence of echocardiographic
evidence of right heart dysfunction (RHD) (7). This parallels a
subgroup analysis of the STEP-IPF study, which demonstrated a
significant improvement in 6-minute-walk distance of 99 m in the
sildenafil patients who had evidence of RHD on echocardiography
(8). Thus, the current subgroup analysis was eagerly anticipated,
with the hope that this too might demonstrate a similar difference.
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